Recruiting soon

SNACSpatial Computing Device with AR/VR for Needle Phobia Exposure Therapy

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study uses a spatial computing device with AR/VR to provide exposure therapy for people with needle phobia. We will assess the treatment's acceptability, feasibility, and any adverse events.

What is being tested

Mixed reality (XR) Exposure Therapy

Behavioral
Who is being recruted

From 11 to 17 Years
+13 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: May 2026
See protocol details

Summary

Principal SponsorStanford University
Study ContactAaron Lulla, MDMore contacts
Last updated: March 24, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: May 1, 2026

Actual date on which the first participant was enrolled.

This study focuses on needle phobia and Blood-Injection-Injury phobia, fears that can affect children, teens, and adults during medical or surgical procedures involving needles. These fears can cause difficulties in care, affecting a person's ability to participate in or receive necessary treatments. Current treatments for these phobias in children and teens are limited, and using medications to manage needle phobia can lead to additional medical complications without addressing the root cause. The study aims to explore the use of Virtual Reality Exposure Therapy (XRET) in children and teens, as recent advancements in technology, like spatial computing and Mixed Reality devices, may enhance engagement and effectiveness of the treatment. The study will evaluate the effectiveness of XRET for children and teens with needle and Blood-Injection-Injury phobias undergoing procedures at LPCH and Stanford Hospital. Participants will undergo XRET, and the study will measure changes in anxiety symptoms related to these phobias. The study will use a validated tool called the APA severity Measure for Specific Phobia (APA-SMS) to assess symptom severity. This scale ranges from 0 to 40, with higher scores indicating greater phobia severity. A decrease in symptom ratings from moderate, severe, or extreme to mild or none by the end of the treatment indicates remission of symptoms.

Official TitleUse of a Spatial Computing Device and Augmented Reality and Virtual Reality for Exposure Therapy for Needle and Blood-Injection-Injury Phobia
Principal SponsorStanford University
Study ContactAaron Lulla, MDMore contacts
Last updated: March 24, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

20 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 11 to 17 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

3 inclusion criteria required to participate
Patients screened with the modified APA severity Measure for Specific Phobia (blood, needles, or injections), and have an individual phobia score rated as moderate, severe, or extreme (as described below)

Patients between the ages of 11-17

Fear of needle

10 exclusion criteria prevent from participating
Virtual Reality headsets do not fit

Legal guardian not present to obtain consent

Adolescent with a significant neurological condition, or major developmental disability

Adolescent with active infection of the face or hand

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Lucile Parkard Children's Hospital

Stanford, United StatesOpen Lucile Parkard Children's Hospital in Google Maps
Recruiting soonOne Study Center